Integration of long-acting antiretroviral therapies and latency-reversing agents for reservoir reduction and viral suppression: a comprehensive review
Article Sidebar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Main Article Content
Abstract
Despite significant advancements in antiretroviral therapy (ART), the persistent latent HIV reservoir remains a major barrier to achieving a complete cure. Current ART regimens effectively suppress viral replication but necessitate lifelong adherence due to their inability to eradicate latent HIV. Long-acting antiretroviral therapies (LA-ARTs) have emerged as an innovation to improve adherence and reduce the burden of daily dosing. Additionally, latency-reversing agents (LRAs) aim to reactivate the latent virus, making it susceptible to immune clearance. The combination of LA-ART and LRAs offers a promising therapeutic approach to address both adherence challenges and reservoir eradication. Objective: This review explores the potential synergy between LA-ART and LRAs, focusing on their individual and combined roles in reducing HIV reservoirs and sustaining viral suppression. Methodology: A systematic search of peer-reviewed articles and clinical studies was conducted following SANRA guidelines. Inclusion criteria included studies involving PLWH, focusing on LA-ART and/or LRAs, and evaluating outcomes such as reservoir reduction and viral suppression. Studies without clinical applicability or reporting relevant outcomes were excluded. Discussion: LA-ART enhances adherence and quality of life by reducing the dosing frequency, while LRAs utilize a “shock and kill” strategy to reactivate the latent virus. Despite their potential, challenges such as suboptimal LRA efficacy, immune clearance limitations, and accessibility barriers persist. Combining these therapies may create a robust treatment framework, but further research is needed to optimize regimens and overcome implementation challenges. This review highlights the need for collaborative efforts in research and policy to refine and integrate these therapies, moving closer to a functional cure for HIV.
Article Details
References
UNAIDS. Global HIV & AIDS statistics — Fact sheet [Internet]. UNAIDS. Available from: https://www.unaids.org/en/resources/fact-sheet
Nakagawa F, May M, Phillips A. Life expectancy living with HIV. Current Opinion in Infectious Diseases [Internet]. 2012 Dec 7;26(1):17–25. Available from: https://doi.org/10.1097/qco.0b013e32835ba6b1 DOI: https://doi.org/10.1097/QCO.0b013e32835ba6b1
Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nature Immunology [Internet]. 2015 May 19;16(6):584–9. Available from: https://doi.org/10.1038/ni.3152 DOI: https://doi.org/10.1038/ni.3152
Chen J, Zhou T, Zhang Y, Luo S, Chen H, Chen D, et al. The reservoir of latent HIV. Frontiers in Cellular and Infection Microbiology [Internet]. 2022 Jul 28;12. Available from: https://doi.org/10.3389/fcimb.2022.945956 DOI: https://doi.org/10.3389/fcimb.2022.945956
McMyn NF, Varriale J, Fray EJ, Zitzmann C, MacLeod H, Lai J, et al. The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy. Journal of Clinical Investigation [Internet]. 2023 Jul 18;133(17). Available from: https://doi.org/10.1172/jci171554 DOI: https://doi.org/10.1172/JCI171554
Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, et al. Long-acting antiretrovirals and HIV treatment adherence. The Lancet HIV [Internet]. 2023 Apr 14;10(5):e332–42. Available from: https://doi.org/10.1016/s2352-3018(23)00051-6 DOI: https://doi.org/10.1016/S2352-3018(23)00051-6
Bricker KM, Chahroudi A, Mavigner M. New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models. Viruses [Internet]. 2021 Aug 6;13(8):1560. Available from: https://doi.org/10.3390/v13081560 DOI: https://doi.org/10.3390/v13081560
Rodari A, Darcis G, Van Lint CM. The current status of latency reversing agents for HIV-1 remission. Annual Review of Virology [Internet]. 2021 Sep 29;8(1):491–514. Available from: https://doi.org/10.1146/annurev-virology-091919-103029 DOI: https://doi.org/10.1146/annurev-virology-091919-103029
Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. Journal of Antimicrobial Chemotherapy [Internet]. 2021 Aug 17;77(2):290–302. Available from: https://doi.org/10.1093/jac/dkab324 DOI: https://doi.org/10.1093/jac/dkab324
Halani S, Tan D, Andany N. Long-acting injectable antiretroviral therapy for HIV-1 infection in adults. Canadian Medical Association Journal [Internet]. 2024 Mar 17;196(10):E341–2. Available from: https://doi.org/10.1503/cmaj.231498 DOI: https://doi.org/10.1503/cmaj.231498
Moreno S, Rivero A, Ventayol P, Falcó V, Torralba M, Schroeder M, et al. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain. Infectious Diseases and Therapy [Internet]. 2023 Jul 14;12(8):2039–55. Available from: https://doi.org/10.1007/s40121-023-00840-y DOI: https://doi.org/10.1007/s40121-023-00840-y
Gurugubelli NS, Gundepalli NSG. Optimizing chemotherapy protocol for diverse patient populations. Journal for International Medical Graduates [Internet]. 2023 Sep 22;2(2). Available from: https://doi.org/10.56570/jimgs.v2i2.127 DOI: https://doi.org/10.56570/jimgs.v2i2.127
Delany‐Moretlwe S, Flexner C, Bauermeister JA. Advancing use of long‐acting and extended delivery HIV prevention and treatment regimens. Journal of the International AIDS Society [Internet]. 2023 Jul 1;26(S2). Available from: https://doi.org/10.1002/jia2.26126 DOI: https://doi.org/10.1002/jia2.26126
Wingood GM, Rubtsova A, DiClemente RJ, Metzger D, Blank M. A new paradigm for optimizing HIV intervention synergy. JAIDS Journal of Acquired Immune Deficiency Syndromes [Internet]. 2013 May 14;63(Supplement 1):S108–13. Available from: https://doi.org/10.1097/qai.0b013e318291fff4 DOI: https://doi.org/10.1097/QAI.0b013e318291fff4
Chomont N, Okoye AA, Favre D, Trautmann L. Wake me up before you go. AIDS [Internet]. 2017 Nov 11;32(3):293–8. Available from: https://doi.org/10.1097/qad.0000000000001695 DOI: https://doi.org/10.1097/QAD.0000000000001695
Ait-Ammar A, Kula A, Darcis G, Verdikt R, De Wit S, Gautier V, et al. Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. Frontiers in Microbiology [Internet]. 2020 Jan 24;10. Available from: https://doi.org/10.3389/fmicb.2019.03060 DOI: https://doi.org/10.3389/fmicb.2019.03060
Tanaka K, Kim Y, Roche M, Lewin SR. The role of latency reversal in HIV cure strategies. Journal of Medical Primatology [Internet]. 2022 Aug 27;51(5):278–83. Available from: https://doi.org/10.1111/jmp.12613 DOI: https://doi.org/10.1111/jmp.12613
Ngo MH, Pankrac J, Ho RCY, Ndashimye E, Pawa R, Ceccacci R, et al. Effective and targeted latency reversal in CD4 + T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection. Emerging Microbes & Infections [Internet]. 2024 Mar 6;13(1). Available from: https://doi.org/10.1080/22221751.2024.2327371 DOI: https://doi.org/10.1080/22221751.2024.2327371
Debrabander Q, Hensley KS, Psomas CK, Bramer W, Mahmoudi T, Van Welzen BJ, et al. The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review. Journal of Virus Eradication [Internet]. 2023 Aug 19;9(3):100342. Available from: https://doi.org/10.1016/j.jve.2023.100342 DOI: https://doi.org/10.1016/j.jve.2023.100342
Ke R, Conway JM, Margolis DM, Perelson AS. Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. JCI Insight [Internet]. 2018 Oct 17;3(20). Available from: https://doi.org/10.1172/jci.insight.123052 DOI: https://doi.org/10.1172/jci.insight.123052
Kula-Pacurar A, Rodari A, Darcis G, Van Lint C. Shocking HIV-1 with immunomodulatory latency reversing agents. Seminars in Immunology [Internet]. 2021 Jan 1;51:101478. Available from: https://doi.org/10.1016/j.smim.2021.101478 DOI: https://doi.org/10.1016/j.smim.2021.101478
Schnell AP, Kohrt S, Thoma-Kress AK. Latency Reversing agents: kick and kill of HTLV-1? International Journal of Molecular Sciences [Internet]. 2021 May 24;22(11):5545. Available from: https://doi.org/10.3390/ijms22115545 DOI: https://doi.org/10.3390/ijms22115545
Kim JT, Zhang TH, Carmona C, Lee B, Seet CS, Kostelny M, et al. Latency reversal plus natural killer cells diminish HIV reservoir in vivo. Nature Communications [Internet]. 2022 Jan 10;13(1). Available from: https://doi.org/10.1038/s41467-021-27647-0 DOI: https://doi.org/10.1038/s41467-021-27647-0
Pardons M, Fromentin R, Pagliuzza A, Routy JP, Chomont N. Latency-Reversing agents induce differential responses in distinct memory CD4 T cell subsets in individuals on antiretroviral therapy. Cell Reports [Internet]. 2019 Nov 1;29(9):2783-2795.e5. Available from: https://doi.org/10.1016/j.celrep.2019.10.101 DOI: https://doi.org/10.1016/j.celrep.2019.10.101